285 related articles for article (PubMed ID: 11702367)
1. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.
Nagore E; Insa A; Sanmartín O
Am J Clin Dermatol; 2000; 1(4):225-34. PubMed ID: 11702367
[TBL] [Abstract][Full Text] [Related]
2. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Kara IO; Sahin B; Erkisi M
Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
[TBL] [Abstract][Full Text] [Related]
3. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Risum S; Langer SW
Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
[TBL] [Abstract][Full Text] [Related]
4. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Webster-Gandy JD; How C; Harrold K
Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
[TBL] [Abstract][Full Text] [Related]
5. The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy.
Janusch M; Fischer M; Marsch WCh; Holzhausen HJ; Kegel T; Helmbold P
Eur J Dermatol; 2006; 16(5):494-9. PubMed ID: 17101468
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases].
Hueso L; Sanmartín O; Nagore E; Botella-Estrada R; Requena C; Llombart B; Serra-Guillén C; Alfaro-Rubio A; Guillén C
Actas Dermosifiliogr; 2008 May; 99(4):281-90. PubMed ID: 18394404
[TBL] [Abstract][Full Text] [Related]
7. The hand-foot-syndrome associated with medical tumor therapy - classification and management.
Degen A; Alter M; Schenck F; Satzger I; Völker B; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2010 Sep; 8(9):652-61. PubMed ID: 20482685
[TBL] [Abstract][Full Text] [Related]
8. A case of docetaxel-induced erythrodysesthesia.
Katoh M; Kadota M; Nishimura Y
J Dermatol; 2004 May; 31(5):403-6. PubMed ID: 15187308
[TBL] [Abstract][Full Text] [Related]
9. Penile involvement with hand-foot syndrome.
Sorscher SM
Am J Clin Dermatol; 2004; 5(3):209-10. PubMed ID: 15186201
[TBL] [Abstract][Full Text] [Related]
10. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
[TBL] [Abstract][Full Text] [Related]
11. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced palmer planter erythrodysesthesia.
Bhasin S; Sunita ; Gupta DK; Kataria SP; Saluja S; Sharma M
J Assoc Physicians India; 2005 Feb; 53():155-6. PubMed ID: 15847041
[TBL] [Abstract][Full Text] [Related]
13. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
[TBL] [Abstract][Full Text] [Related]
14. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced acral erythema (CIAE) with bullous reaction.
Azurdia RM; Clark RE; Friedmann PS
Clin Exp Dermatol; 1999 Mar; 24(2):64-6. PubMed ID: 10233654
[TBL] [Abstract][Full Text] [Related]
16. Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia.
Crawford JH; Eikelboom JW; McQuillan A
Eur J Haematol; 2002; 69(5-6):315-7. PubMed ID: 12460237
[TBL] [Abstract][Full Text] [Related]
17. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
Fabian CJ; Molina R; Slavik M; Dahlberg S; Giri S; Stephens R
Invest New Drugs; 1990 Feb; 8(1):57-63. PubMed ID: 2345070
[TBL] [Abstract][Full Text] [Related]
18. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
[TBL] [Abstract][Full Text] [Related]
19. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Bednaríková D; Kocák I
Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V
Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
